JP2021532784A5 - - Google Patents
Info
- Publication number
- JP2021532784A5 JP2021532784A5 JP2021505393A JP2021505393A JP2021532784A5 JP 2021532784 A5 JP2021532784 A5 JP 2021532784A5 JP 2021505393 A JP2021505393 A JP 2021505393A JP 2021505393 A JP2021505393 A JP 2021505393A JP 2021532784 A5 JP2021532784 A5 JP 2021532784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- pharmaceutically acceptable
- acceptable salt
- oligonucleotide complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711894P | 2018-07-30 | 2018-07-30 | |
| US62/711,894 | 2018-07-30 | ||
| PCT/US2019/043920 WO2020028254A1 (en) | 2018-07-30 | 2019-07-29 | Trimeric peptides for antisense delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532784A JP2021532784A (ja) | 2021-12-02 |
| JP2021532784A5 true JP2021532784A5 (enExample) | 2022-07-29 |
| JP7564087B2 JP7564087B2 (ja) | 2024-10-08 |
Family
ID=69230560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505393A Active JP7564087B2 (ja) | 2018-07-30 | 2019-07-29 | アンチセンス送達のための三量体ペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12168059B2 (enExample) |
| EP (1) | EP3829597A4 (enExample) |
| JP (1) | JP7564087B2 (enExample) |
| TW (1) | TW202019442A (enExample) |
| WO (1) | WO2020028254A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765030A4 (en) * | 2018-03-16 | 2022-01-26 | Sarepta Therapeutics, Inc. | CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION |
| US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| WO2021150867A1 (en) * | 2020-01-24 | 2021-07-29 | Sarepta Therapeutics, Inc. | Designing antisense oligonucleotide delivery peptides by interpretable machine learning |
| AU2022271873A1 (en) * | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
| WO2022240760A2 (en) * | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING |
| EP4337263A1 (en) * | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
| KR20240037299A (ko) * | 2021-07-23 | 2024-03-21 | 빔 테라퓨틱스, 인크. | Crispr/cas 편집 시스템용 가이드 rna |
| WO2023191953A1 (en) | 2022-03-26 | 2023-10-05 | University Of Rhode Island Board Of Trustees | Pnictogen-containing heterocyclic compounds and their use |
| WO2023192510A1 (en) * | 2022-03-31 | 2023-10-05 | Entrada Therapeutics, Inc. | β-CATENIN ANTIBODIES |
| WO2026080471A2 (en) | 2024-10-07 | 2026-04-16 | Flagship Pioneering Innovations Vi, Llc | Compositions of trem conjugates and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092114A1 (en) * | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| WO2015069665A1 (en) * | 2013-11-06 | 2015-05-14 | Rain Bioscience, Inc. | Intracellular delivery system for oligomers having low renal clearance rate |
| AU2016264471B2 (en) * | 2015-05-19 | 2022-01-27 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2019
- 2019-07-29 JP JP2021505393A patent/JP7564087B2/ja active Active
- 2019-07-29 WO PCT/US2019/043920 patent/WO2020028254A1/en not_active Ceased
- 2019-07-29 TW TW108126853A patent/TW202019442A/zh unknown
- 2019-07-29 US US17/264,163 patent/US12168059B2/en active Active
- 2019-07-29 EP EP19844253.5A patent/EP3829597A4/en active Pending
-
2024
- 2024-10-31 US US18/933,636 patent/US20250161469A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532784A5 (enExample) | ||
| JP2758988B2 (ja) | ペプチド核酸 | |
| US10793605B2 (en) | Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids | |
| CN101547932B (zh) | 核苷芳基氨基磷酸酯及其作为抗病毒制剂处理丙型肝炎病毒的应用 | |
| FI120261B (fi) | PNA-synteesi käyttämällä heikkojen happojen suhteen labiilia aminonsuojaryhmää | |
| JP2018530560A5 (enExample) | ||
| JP2022546609A5 (enExample) | ||
| JP2020537654A5 (enExample) | ||
| NZ243000A (en) | Tachykinin derivative | |
| JP2021518361A5 (enExample) | ||
| US6713602B1 (en) | Synthetic procedures for peptide nucleic acids | |
| De Cola et al. | Carboxyalkyl peptoid PNAs: synthesis and hybridization properties | |
| ITMI951450A1 (it) | Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati | |
| AU2024265463A1 (en) | Preparation of peptide inhibitor of interleukin-23 receptor and use thereof | |
| SK2793A3 (en) | Polypeptide compounds with ability release of growth hormone | |
| JP2021515005A5 (enExample) | ||
| HUE028918T2 (en) | Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt | |
| JP2025513521A5 (enExample) | ||
| JPWO2023127752A5 (enExample) | ||
| AU2022291626A1 (en) | Improved process for preparing imetelstat | |
| JP2023546205A (ja) | コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト | |
| JP2020537652A5 (enExample) | ||
| US7038037B2 (en) | Method for sequential support-bound synthesis of conjugated oligomeric compounds | |
| US9017673B2 (en) | Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy | |
| JP2024537711A5 (enExample) |